An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes

European Journal of Cancer

Volumn 38, Issue 6, 2002, Pages 773-778

  Awada, A ^a   Biganzoli, L ^b   Cufer, T ^c   Beex, L ^d   Lohrisch, C ^b   Batter, V ^b   Hamilton, A ^b   Nooij, M ^e   Piccart, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anthracycline and taxane pre treated; Combination chemotherapy; Metastatic breast cancer

Indexed keywords

AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS;

EID: 0036206403     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00427-0     Document Type: Article

References (24)

1. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
2. A multicenter phase II trial of XelodaTM (capecitabine) in taxane-refractory metastatic breast cancer
3. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
4. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - A phase II study
5. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
6. Can patients with metastatic breast cancer (MBC) pre-treated with cyclophosphamide, anthracyclines or Taxol respond to infusion of 5-FU (FUI)? Rationale for FUI-containing chemotherapy
7. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer
8. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
9. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: Results of a phase I study
10. Advanced breast cancer: A phase II trial with gemcitabine
11. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin+paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial
12. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells
13. Reporting results of cancer treatment
14. Results of a large phase III trial of Xeloda/Taxotere combination therapy vs taxotere monotherapy in metastatic breast cancer (MBC)
15. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: Preliminary results of a phase II trial
16. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor
17. Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial
18. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients
19. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group
20. Gemcitabine and vinorelbine in pretreated advanced breast cancer: A pilot study
21. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic Cooperative Oncology Group Phase II study
22. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer
23. Infusional fluoracil+gemcitabine is an active combination for patients with metastatic breast cancer refractory to anthracyclines and taxanes
24. Treatment of metasatic breast cancer with continous infusional 5 fluorouracil